A Single-Arm, Open-Label Phase II Study of ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma.
Sarah L P AtkinsYoshimi Endo GreerSarah JenkinsMargaret E Gatti-MaysNicole HoustonSunmin LeeMin-Jung LeeShraddha RastogiNahoko SatoChristina BurksChristina M AnnunziataJung-Min LeeKunio NagashimaJane B TrepelStanley LipkowitzAlexandra S ZimmerPublished in: The oncologist (2023)
ONC201 monotherapy did not induce objective responses in recurrent or refractory metastatic breast or endometrial cancer at the RP2D dose of 625 mg weekly but had an acceptable safety profile (ClinicalTrials.gov Identifier: NCT03394027).